Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to TNS1 (ENSG00000295147) is a predicted long non-coding RNA that is transcribed from the opposite strand of the TNS1 gene locus. Like other natural antisense transcripts, it may theoretically regulate the expression of the sense TNS1 gene by mechanisms such as modifying chromatin states, influencing RNA processing, or competing for regulatory factors, although there is currently no direct evidence for any functional role. Antisense transcription in general is known to be widespread in the genome and can modulate the dynamics of sense transcript production and stability, potentially by affecting chromatin architecture and nucleosome positioning; however, these features have not been specifically demonstrated for ENSG00000295147[1][3]. There are no known clinical, pharmacological, or disease implications for this transcript at present.
Not applicable; no drugs or interventions are known to act on this transcript
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to TNS1 (ENSG00000295147).